

### **PCT**

REC'D 27 APR 2004

PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

			nt's file reference 62WO	FOR FURTHER ACTION  See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)						
International application No. PCT/EP 03/00448				International filing date (d. 08.01.2003	ay/month/year)	Priority date (day/month/year) 08.01.2002				
Intern	ational	Pater	nt Classification (IPC) or b	oth national classification an	nd IPC	·				
C07	C07K14/575									
Appli INS	Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA et al.									
<u> </u>										
1.	<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> </ol>									
2.	This REPORT consists of a total of 4 sheets, including this cover sheet.									
	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).									
	These annexes consist of a total of sheets.									
3.	3. This report contains indications relating to the following items:									
	ı	$\boxtimes$	Basis of the opinion			·				
	11		Priority							
	Ш		Non-establishment of	f opinion with regard to no	ovelty, inventive step	and industrial applicability				
	IV		Lack of unity of inven	ition						
	V Neasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement									
	VI		Certain documents c							
	VII			international application						
	VIII   Certain observations on the international application									
Date of submission of the demand					Date of completion of	this report				
03.07.2003					26.04.2004					
Name and mailing address of the international preliminary examining authority:					Authorized Officer	egelitzhes Pelanteg.				
European Patent Office D-80298 Munich					Stolz, B	)				
Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465					Telephone No. +49 8	39 2399-8416				



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/00448

I. Basis of the	report
-----------------	--------

1.	the	With regard to the <b>elements</b> of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):								
	Des	cription, Pages								
	1-23	3	as originally filed							
	Claims, Numbers									
	1-12	2	as originally filed							
	Dra	Drawings, Sheets								
	1/12	?-1.2/12	as originally filed							
2.	With lang	regard to the <b>language</b> , all the elements marked above were available or furnished to this Authority in the juage in which the international application was filed, unless otherwise indicated under this item.								
	The	These elements were available or furnished to this Authority in the following language: , which is:								
	☐ the language of a translation furnished for the purposes of the international search (under Rule 23									
		the language of publ	ication of the international application (under Rule 48.3(b)).							
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under 3).							
3.	With regard to any <b>nucleotide and/or amino acid sequence</b> disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:									
		contained in the international application in written form.								
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosu in the international application as filed has been furnished.								
		The statement that t listing has been furn	he information recorded in computer readable form is identical to the written sequence ished.							
4.	The	The amendments have resulted in the cancellation of:								
		the description,	pages:							
		the claims,	Nos.:							

sheets:

the drawings,



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/00448

5. 
This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-12

No: Claims

Inventive step (IS) Yes: Claims


No: Claims 1-12

Industrial applicability (IA) Yes: Claims 1-12

No: Claims

2. Citations and explanations

see separate sheet



International application No. PCT/EP03/00448

**EXAMINATION REPORT - SEPARATE SHEET** 

- The application discloses prolactin receptor antagonists with antiproliferative 1. activity consisting of N-terminally modified/truncated hPRL with a sterically hindering mutation in the second binding site.
- 2. The subject matter of claims 1 to 12 has not been disclosed in the prior art.
- The subject matter of claims 1 to 12 lacks an inventive step in view of Bernichtein 3. et al. in combination with Goffin et al..

Bernichtein et al. provides a preliminary account of studies on the effect of Nterminal deletions on the activity and multimerization of hPRL. The aim of their study is the design of more potent hPRL antagonists. The abstract discloses an effect of the removal of the N-terminal loop on the tendency to multimerize. The abstract explicitly suggests the combination of N-terminally deleted hPRL with site 2 analogs such as disclosed in Goffin et al., in order to obtain more potent hPRL antagonists.

Following the explicit teaching of Bernichtein et al., i.e. by combining the two types of mutations, the person of skill would have found himself in a one way street situation. He would have tested the molecules by the methods known in the art and would unavoidably have found PRL antagonists having lost their agonistic activity.

Therefore, the claims are considered to lack an inventive step.